Muscle Preservation in the GLP-1 Era: The BELIEVE Trial Message

As GLP-1 receptor agonists become standard for obesity treatment, the muscle loss (lean mass loss) accompanying them has emerged as a new clinical target. The BELIEVE trial, presented at the ADA’s 85th Scientific Sessions, released early data on bimagrumab plus semaglutide as a new approach to muscle preservation.

How serious is GLP-1 muscle loss

GLP-1 agonists (semaglutide, tirzepatide) deliver powerful weight loss exceeding 25%. They also produce 15-40% of total weight loss from muscle.

This proportion partially occurs in any caloric restriction, but in GLP-1 users it accelerates. Appetite suppression reduces protein intake, and reduced activity compounds the loss.

The consequences. Lower basal metabolic rate, reduced strength, increased sarcopenia risk, faster weight regain on drug discontinuation. Particularly dangerous in adults 65+ and postmenopausal women.

What makes BELIEVE different

BELIEVE is a randomized trial combining bimagrumab with semaglutide. Bimagrumab is a monoclonal antibody that blocks GDF8 (myostatin) and activin A activity, reinforcing muscle growth signaling.

GDF8 (growth differentiation factor 8, myostatin) is a signal that suppresses muscle growth. Blocking it allows muscle growth to proceed. The mechanism is well-established in animals and has been studied in sports medicine and sarcopenia therapy in humans.

The BELIEVE hypothesis: while semaglutide drives weight loss, bimagrumab simultaneously blocks the muscle loss component, preserving body composition while keeping the weight loss benefit.

Initial data

ADA-presented data showed better muscle preservation in the bimagrumab + semaglutide combination arm. Specific numbers reflect the conference presentation; larger follow-up trials are expected over the next 1-2 years.

The combination’s safety profile was generally favorable, though some bimagrumab-specific side effects (diarrhea, muscle pain) were reported.

Non-pharmacological preservation strategies

Beyond drug combinations, validated non-drug strategies are available for GLP-1 users.

High protein intake. 1.2-1.6 g per kg body weight per day is recommended during GLP-1 use, higher than the standard 0.8 g/kg recommendation. With appetite suppression, prioritizing protein shakes, chicken breast, tofu, and Greek yogurt helps.

Resistance training. 2-3 sessions per week of compound movements is the strongest non-drug preservation. Should start with GLP-1, not after.

HMB 3 g/day. β-hydroxy-β-methylbutyrate is a leucine metabolite that suppresses muscle protein breakdown. Meaningful effects reported in adults 65+ with sarcopenia. Likely effective in GLP-1 users too.

Leucine 6 g/day. The key trigger for muscle protein synthesis. Research suggests 4 g+ leucine per protein meal is enough to activate mTOR.

Creatine 3-5 g/day. Maintains muscle energy systems. Safety well-established.

Omega-3 2-4 g/day. Multiple studies show improved muscle protein synthesis efficiency.

Vitamin D 800-1,000 IU/day. Direct effect on muscle function when deficient.

This layered matrix can complement or substitute for BELIEVE-style drug combinations.

Who is at greatest risk

Three groups are most vulnerable to GLP-1 muscle loss.

Adults 65+. Sarcopenia risk is already elevated. Additional GLP-1 loss is hard to recover.

Postmenopausal women. Hormonal change has already reduced muscle protein synthesis efficiency.

Normal-BMI obesity (skinny fat). Outwardly normal BMI but high body fat percentage and low muscle mass. After GLP-1, fat decreases but muscle declines further, transitioning toward sarcopenic obesity.

Connection to this quarter’s data

Combined with GLP-1 aesthetic behavior data (52% facial change concern, 32% first-time aesthetic), Vitamin K2 TAKEOVER (EMD shortening in 65+), and Mayo Clinic senolytic postmenopausal bone trial, the picture sharpens.

The GLP-1 era is creating new categories. Aesthetic procedures for facial change. D3 + K2 + calcium + senolytics for bone loss. Protein + HMB + resistance training + (BELIEVE combination) for muscle loss. Quality of weight loss, not just weight loss, becomes the standard.

Daily guide

Before or alongside starting GLP-1, check the following. Adequate protein intake (shakes, meat, soy prioritized). Resistance training 2-3 times weekly is feasible. Vitamin D level measured and adequate. For adults 65+, consider HMB and K2 supplementation.

GLP-1 is an effective tool. The quality of its effect depends on accompanying strategy. Drug alone yields lower-quality weight loss and faster regain on discontinuation.